Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-565-000"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20110215.29.2-565-000"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs |
vice-chair; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2013-01-24)3,3
|
lpv:translated text |
"Madam President, ladies and gentlemen, first of all, I would like to congratulate the rapporteur, Mrs Grossetête, on the good work she has accomplished. Falsified medicinal products are dangerous because of their huge public health impact, not to mention their economic impact.
Although the compromise text is a decided improvement over the provisions of the 2001 directive, it does not touch on certain issues that I think are fundamental, which I would like to mention here. Manufacturers of active substances based in third countries should be subject to inspections by the Member State to which those substances are destined, to be mediated by the competent authorities of the third country in question.
Medicinal products should be clearly traceable as regards the manufacturer and the country of origin of the various active substances whenever this information is not specified in the new formulation. The issue of Internet sales remains unresolved.
Nonetheless, I would stress that the report is positive overall and makes improvements, and I support Mrs Grossetête in favour of the compromise."@en1
|
lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples